A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis
NCT01272089
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
300
Enrollment
INDUSTRY
Sponsor class
Conditions
Allergic Conjunctivitis
Interventions
DRUG:
Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
Sponsor
Alcon Research